Chimerix Inc (STU:CXF)
€ 3.03 0.21 (7.45%) Market Cap: 298.58 Mil Enterprise Value: 168.48 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 51/100

Chimerix Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 12, 2020 / 09:15PM GMT
Release Date Price: €2.68 (-2.55%)
Andrew E. Singer
Credit Suisse Group AG - MD of Healthcare Investment Banking Division

Hello, and good afternoon. It's Andy Singer with Credit Suisse. I'm very happy to introduce to you the management team of Chimerix, the team that I've known for many years. They have a very successful track record in business operations, drug development and strategy with a very successful exit at their prior company, Endocyte, which as you, I'm sure, aware was sold to Novartis and a very successful exit, and now the team is at Chimerix. And here today to tell you about their programs is Mike Sherman, who's the Chief Executive Officer; Mike Andriole, who's the CBO and CFO; and then Allen Melemed, who's the Chief Medical Officer.

So with that, I'll turn it over to Mike.

Michael A. Sherman
Chimerix, Inc. - CEO, President & Director

Thanks, Andy. And let me bring my presentation up and make sure we're in sharing mode here. Great. Andy, thanks for having us. Always great to present at this conference, and it's particularly fun to present here when we've got some

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot